Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 9,409

Document Document Title
WO/2024/022167A1
The present invention provides a novel camptothecin derivative compound, a pharmaceutically acceptable salt, a stereoisomer, or a prodrug thereof, and a method for preparing same and use thereof. The compound has a structure represented ...  
WO/2024/022444A1
The present disclosure relates to a fused ring compound, a preparation method therefor and a medicinal application thereof. Specifically, the present disclosure relates to a fused ring compound represented by general formula (IN), a prep...  
WO/2024/026061A1
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject i...  
WO/2024/019103A1
Provided is a compound that is effective as an active ingredient in a therapeutic pharmaceutical composition for pancreatic cancer. Having studied compounds that are effective as active ingredients in a therapeutic pharmaceutical compo...  
WO/2024/017392A1
Disclosed in the present invention are a pyrimidine ring compound, an intermediate thereof, a pharmaceutical composition thereof, and a use thereof. The pyrimidine ring compound is a compound as represented by formula (I) or formula (II)...  
WO/2024/020522A1
The present disclosure relates to compounds that act as degraders of IRAK-4 protein kinase; pharmaceutical compositions comprising compounds of Formula (I); and methods of treating diseases and disorders associated with cancer and inflam...  
WO/2024/018403A1
The present disclosure includes substituted imidazoamide compounds of Formula (I), analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the disclosure can be used to treat, ameliorate, and...  
WO/2024/020084A1
Provided herein are compounds and compositions thereof for modulating IRAK4. In some embodiments, the compounds and compositions are provided for treatment of inflammatory or autoimmune diseases.  
WO/2024/020068A1
Disclosed are bacterial topoisomerase inhibitors with antibacterial activity, including against fluoroquinolone-resistant Staphylococcus aureus, comprising structural domains: a) a left-hand side (LHS) usually comprising a fused bicyclic...  
WO/2024/020034A1
Disclosed herein are compounds that are Cbl-b inhibitors having a structure according to Formula (II), and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment ...  
WO/2024/017381A1
The present application relates to a compound for inhibiting IRAK4 activity and a use thereof, and specifically provides a compound as represented by formula A, or an enantiomer, a diastereoisomer, a racemate, a tautomer, a stereoisomer,...  
WO/2024/015503A1
Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.  
WO/2024/015497A1
This disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, in which all of the variables in Formula (I) are as defined in the application. The compounds of this disclosure are capable of inhibiting ...  
WO/2024/012512A1
Provided are a carbazole derivative and a use thereof. The structural formula of the carbazole derivative is as shown in formula (I), and the carbazole derivative has a condensed carbazole structure. The compound can be applied to an org...  
WO/2024/012519A1
Provided in the present invention are a fused ring aromatic compound having a broad-spectrum inhibition effect on KRAS mutation, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. As shown in formula ...  
WO/2024/012469A1
The present invention relates to a carbazole derivative and use thereof in an organic light-emitting element. The carbazole derivative has a fused carbazole structure, a high triplet state energy level is achieved, and conjugation of a c...  
WO/2024/012456A1
Disclosed are a piperazine bridge-substituted heterocyclic pyrimidine compound or a pharmaceutically acceptable salt thereof. Specifically disclosed is a compound represented by formula (III-1) or a pharmaceutically acceptable salt thereof.  
WO/2024/011883A1
The present invention relates to a WEE1 inhibitor, preparation therefor and a use thereof. The structure of the WEE1 inhibitor is represented by formula (I). The present invention relates to a compound of formula (I), or a stereoisomer t...  
WO/2024/008179A1
Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D.  
WO/2024/008833A1
A prodrug kit for multifactorial dynamic chemotherapy comprises N different small-molecule- drug-conjugates selected from the group comprising Si = Fci―Li―Cti with i = 1, 2, 3, …., 360 wherein 2 ≤ N ≤ 360, Fci is a moiety that ...  
WO/2024/009191A1
The invention relates to compounds of Formula (I)–(VII), or pharmaceutically acceptable salts thereof, to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such pro...  
WO/2024/008178A1
Provided are a compound of formula (I), and a stereoisomer, tautomer, deuterated product or pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and an application...  
WO/2024/008068A1
Provided herein are KRAS mutant protein inhibitors of formula (I), a composition containing the same and the use thereof.  
WO/2024/007997A1
Disclosed in the present invention are a crystal form of a pyridone polycyclic derivative and a preparation method therefor, and particularly a crystal form of a compound as represented by formula (I) and a preparation method therefor.  
WO/2024/008088A1
Disclosed are a class of compounds as TRK inhibitor drugs or RET inhibitor drugs and use thereof. Specifically, disclosed is use of a compound represented by formula (G), or an isotope-labeled compound thereof, or an optical isomer, a ge...  
WO/2024/002377A1
Provided is a class of compounds with methyltransferase inhibitory activity. Specifically, provided is a class of compounds with PRMT5 inhibitory activity. The compounds can be used for preparing a pharmaceutical composition for treating...  
WO/2024/005123A1
A conjugate, in which an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein that has an amino acid sequence represented by any one of the even numbered SEQ ID NOS: 2 to 30 or an amino acid sequence hav...  
WO/2024/006493A1
This disclosure relates to compounds of Formula (I), or pharmaceutically acceptable salt thereof: Formula (I) in which all of the variables are as defined in the application. The compounds of the present disclosure are capable of inhibit...  
WO/2024/002934A1
The present invention relates to 8-heterocyclic-3-(phenylsulfonyl)-[1,2,3] triazolo[1,5a]quinazolin-5(4H)-one derivatives and pharmaceutical compositions thereof as well as to their uses in methods of reducing the virulence of bacteria (...  
WO/2024/002373A1
The present invention relates to a substituted pyrimidine-fused ring inhibitor, a method for preparing same, and use thereof. Specifically, the compound of the present invention has a structure represented by formula (I). Further disclos...  
WO/2023/246914A1
Disclosed are a heterocyclic substituted pyrimidopyran compound and use thereof. In particular, disclosed is a compound represented by formula (VII) and a pharmaceutically acceptable salt thereof.  
WO/2023/246371A1
The present application discloses a small molecule compound having a pyrimidothiophene structure, and a use thereof. By means of inhibiting activity of the cyclin-dependent kinase (CDK) family, the small molecule compound can block the c...  
WO/2023/246903A1
The present invention provides a selenium-containing heterocyclic compound with a structure represented by formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof or a prodrug molecule thereof or a deuterated ...  
WO/2023/250430A1
The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 12 (CDK12), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same  
WO/2023/246837A1
The present invention relates to a class of compounds having a pyrimido-six-membered ring structure, pharmaceutical compositions comprising same, and use thereof. The compounds have a structure represented by formula (I) below. Experimen...  
WO/2023/244639A1
The present disclosure relates to methods of treating cancer in a subject, comprising analyzing one or more biological sample(s) for the presence of a first genetic marker and administering an EGFR inhibitor to the subject if the presenc...  
WO/2023/241552A1
The present disclosure provides salt and/or crystal form for compounds, especially for compounds as casein kinase inhibitors.  
WO/2023/241608A1
The present application relates to compounds of formula (I) and formula (1'), which are useful as inhibitors of CSF-1R in the treatment of various diseases.  
WO/2023/241618A1
Disclosed are a series of aminopyrimidine compounds and use thereof, and specifically disclosed are a compound represented by formula (XI), a stereoisomer thereof and a pharmaceutically acceptable salt thereof, and use thereof.  
WO/2023/244806A1
Disclosed are compounds of formula I, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, that are useful for modulating or degrading protein which is expressed from one or more SWI/SNF-related matrix-assoc...  
WO/2023/240920A1
The present invention relates to a sulfur-containing artemisinin analogue dimer, and a preparation method therefor and the use thereof, which belong to the technical field of pharmaceutical chemistry. The sulfur-containing artemisinin an...  
WO/2023/240038A1
This disclosure provides compounds of Formula (I) (e.g., Formula (I-aa) (e.g., Formula (I-aa-1), (I-aa-2), (I-aa-3), (I-aa-4), (I-aa-5), or (I-aa-6)), Formula (I-a) (e.g., Formula (I-a-1), (I-a-2), (I-a-3), (I-a-4), (I-a-5), or (I-a-6)),...  
WO/2023/238930A1
Provided are novel compounds which are analogues to be removed from APIs and formulations. Also provided are standard products of analogues to be used in controlling the qualities of medicines. Analogue 1: 3-ethyl-4-\{4-[4-(1-methyl-1H-p...  
WO/2023/240189A1
The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.  
WO/2023/240188A1
The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.  
WO/2023/238919A1
Provided is an anticancer agent capable of efficaciously acting on a Ras mutated cancer. The present invention provides a hybrid type compound, in which trametinib is linked to an Akt inhibitor via a linker, or a salt thereof.  
WO/2023/230968A1
Provided are an SHP2 inhibitor, and a crystal form thereof, a preparation method therefor, and a use thereof. Provided are a crystal form B of a compound as shown in formula (I), a compound as shown in formula (II) and a crystal form A t...  
WO/2023/232776A1
The present invention relates to compounds of formula (I), wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.  
WO/2023/232135A1
Disclosed are a compound as represented by formula I; a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing same; and the use thereof as a PDE4B inhibitor in the preparation of a drug fo...  
WO/2023/233130A1
The present invention relates to compounds of formula I shown below: wherein R1, X2, X3, X4, X5, X6, X7, X8 and X9 are each as defined in the application. The present invention also relates to processes for the preparation of these compo...  

Matches 101 - 150 out of 9,409